LEXICON PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Mar 7, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 7, 2025

LXRX$1.86+2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands)

Accumulated
Additional · Other
Common Stock · Preferred Stock · Paid-In · Accumulated · Comprehensive · Treasury
	Shares	Par Value	Shares	Par Value	Capital	Deficit	Income (Loss)	Stock	Total
Balance at December 31, 2021	150,082	$150	—	$—	$1,608,749	$(1,487,776)	$(10)	$(7,518)	$113,595
Stock-based compensation	—	—	—	—	11,520	—	—	—	11,520
Issuance of common stock under Equity Incentive Plans	32	—	—	—	—	—	—	—	—
Issuance of common stock, net of issuance fees	39,100	39	—	—	94,166	—	—	—	94,205
Issuance of equity-classified warrants	—	—	—	—	1,030	—	—	—	1,030
Issuance of treasury stock	—	—	—	—	(6,321)	—	—	6,321	—
Repurchase of common stock	—	—	—	—	—	—	—	(864)	(864)
Net loss	—	—	—	—	—	(101,944)	—	—	(101,944)
Unrealized loss on investments	—	—	—	—	—	—	(418)	—	(418)
Balance at December 31, 2022	189,214	$189	—	$—	$1,709,144	$(1,589,720)	$(428)	$(2,061)	$117,124
Issuance of equity-classified warrants	—	—	—	—	307	—	—	—	307
Stock-based compensation	—	—	—	—	14,340	—	—	—	14,340
Issuance of common stock, net of fees	55,288	55	—	—	138,768	—	—	—	138,823
Issuance of common stock under Equity Incentive Plans	1,291	1	—	—	(1)	—	—	—	—
Repurchase of common stock	—	—	—	—	—	—	—	(824)	(824)
Net loss	—	—	—	—	—	(177,119)	—	—	(177,119)
Unrealized gain on investments	—	—	—	—	—	—	459	—	459
Balance at December 31, 2023	245,793	$245	—	$—	$1,862,558	$(1,766,839)	$31	$(2,885)	$93,110
Stock-based compensation	—	—	—	—	13,499	—	—	—	13,499
Issuance of preferred stock, net of fees	—	—	2,304	23	241,299	—	—	—	241,322
Issuance of common stock under Equity Incentive Plans	2,020	3	—	—	61	—	—	—	64
Repurchase of common stock	—	—	—	—	—	—	—	(1,730)	(1,730)
Conversion of preferred stock to common stock	115,207	115	(2,304)	(23)	(92)	—	—	—	—
Net loss	—	—	—	—	—	(200,403)	—	—	(200,403)
Unrealized gain on investments	—	—	—	—	—	—	88	—	88
Balance at December 31, 2024	363,020	$363	—	$—	$2,117,325	$(1,967,242)	$119	$(4,615)	$145,950

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.